Canada · Delayed Price · Currency is CAD Cipher Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw a 10% revenue decline due to lower U.S. Natroba sales, but strong Canadian Epuris growth and cost efficiencies maintained high profitability, with adjusted EBITDA margins at 57%. Expanded public drug plan coverage for Epuris and new U.S. retail initiatives are expected to drive future growth.
-
Q1 2026 saw 4% revenue growth, 25% higher adjusted EBITDA, and a 138% increase in net income year-over-year, driven by strong U.S. Natroba performance and improved margins. Full debt repayment and a renewed share buyback highlight robust cash flow and disciplined capital allocation.
Fiscal Year 2025
-
Revenue and earnings more than doubled in 2025, driven by Natroba's strong US performance and a stable Canadian base. The new DTC platform and upcoming Canadian launch are expected to fuel further growth, while licensing revenue faces pressure from generics.
-
Q3 2025 saw strong revenue and profit growth, led by Natroba, with significant debt reduction and robust free cash flow. Licensing revenue declined due to generic competition, but new DTC and global expansion strategies are underway. Several state Medicaid bids for Natroba are pending.
-
Record Q2 2025 net revenue and EBITDA were driven by strong NATROBA sales and growth in the Canadian portfolio. Significant deleveraging and capital returns were achieved, while U.S. licensing revenue declined due to generic competition.
-
Q1 2025 saw a 105% revenue increase to $12M, driven by Natroba's strong U.S. launch and robust Canadian sales. Licensing revenue declined due to generics, but adjusted EBITDA rose 73%. Natroba's Medicaid win in Illinois and a $15M debt repayment post-quarter highlight key developments.
Fiscal Year 2024
-
Revenue and earnings surged in 2024, driven by the Natroba acquisition and strong Epuris growth, despite lower U.S. licensing revenue. Direct commercialization of Natroba and global expansion efforts are expected to fuel further growth, with robust cash flow supporting share repurchases.
-
Q3 revenue surged 71% year-over-year, driven by the Natroba acquisition, while gross margin rose to 79%. Integration and transition costs impacted earnings, but normalization and further growth are expected in 2025 as the company pursues additional product acquisitions and licensing deals.
-
Cipher's acquisition of Natroba has doubled sales and EBITDA, with plans to expand market share in the U.S., launch in Canada, and out-license globally. The company maintains strong margins, a robust pipeline, and disciplined financial management.
-
Q2 2024 saw stable legacy business performance and the transformative acquisition of Natroba, expected to drive significant growth in the U.S. and globally. MOB-015 achieved market leadership in Sweden and is set for Canadian launch in 2026.